Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
Clinical trial NCT04984018 · UNKNOWN
Trial details
- NCT number
- NCT04984018
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-01
- Primary completion
- 2022-12-31
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.